The combined application of ALC+quercetin in an animal model of Alzheimer's disease also significantly reduced hippocampus levels of inflammatory biomarkers, like TNF-α and IL-6 [59]. The gene discussed is TNF; the disease is early-onset autosomal dominant Alzheimer disease.